Pathogenesis of antibody-drug conjugates-induced interstitial lung disease
10.12354/j.issn.1000-8179.2024.20240908
- VernacularTitle:抗体偶联药物诱导的间质性肺病的发病机制
- Author:
Zhao CUICUI
1
;
Zhang CHUANGUI
Author Information
1. 天津医科大学肿瘤医院特需病房,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)
- Keywords:
drug-induced interstitial lung disease(DI-ILD);
interstitial lung disease;
anticancer drugs;
antibody-drug conjugates(ADCs);
human epidermal growth factor receptor 2(HER2)
- From:
Chinese Journal of Clinical Oncology
2024;51(15):775-779
- CountryChina
- Language:Chinese
-
Abstract:
Drug-induced interstitial lung disease(DI-ILD)is the most common form of drug-induced pulmonary adverse events,with antican-cer drugs being the primary cause.DI-ILD first gained attention as a notable adverse event due to the use of antibody-drug conjugates(ADC).As the development of drugs,particularly ADCs,continues to expand and more ADCs are approved or nearing approved for clinical use,DI-ILD has become an area of growing concern.However,the mechanisms by which ADCs induce ILD remain unclear.This article reviews the mechanisms of DI-ILD in the most commonly used ADCs targeting human epidermal growth factor receptor 2(HER2).
